For the past 30 years, John Caldwell felt like managing his type 1 diabetes was a full-time job. Now with the MiniMed 670G system, John worries less about managing his diabetes and spends more time doing the things he enjoys – extreme sports, such as skydiving, biking, snowboarding, hiking, and backpacking. John is one of the MiniMed 670G system clinical trial participants who continued on the therapy after the trial concluded. He talks about the impact the hybrid closed loop system has on his life.
Family members of people with diabetes have a really tough job. They worry about you more than you do yourself. My wife is my partner in life and in my diabetes management. She would worry about me going low at night, because I’ve had scary hypoglycemic episodes in the past. With the MiniMed 670G system, this doesn’t happen anymore and that is a huge relief to her. She knows when my blood glucose (BG) levels are under control, it helps both of us live life to the fullest.
The system has the biggest impact on my sleep and diet. My BG level are more stable at night and before meals, so I sleep in range at night and don’t delay meals as I used to. Prior to the MiniMed 670G system, I woke up in the 200’s every morning. It was defeating to feel like I wasn’t in control first thing each day. It was a constant reminder that no matter how hard I tried, sometimes my body would do what it wanted and I couldn’t do anything about it. The MiniMed 670G system does a great job maintaining stable glucose levels and takes away some of that frustration.
What’s ridiculously cool about the new system is that it makes extreme sports easier. For example, when I skydive, it’s important my BG isn’t low before jumping out of the plane. I love that I can set a temporary target of 150 mg/dL, check my BG before I get on a plane and not to worry about my levels. Before, the normal routine for me would include battling highs and lows!
Travelling in Control
I travel internationally a couple of times a year, sometimes spending up to 30 hours in transit with varying sleeping and eating schedules. Between the long flights and drastic time zone changes, staying in control used to be a challenge. With the MiniMed 670G system, I can just adjust the time zone and let the system do the rest. It’s amazing.
Trusting the System
I had to transform how I thought about managing my diabetes, and trust the system to do its job. For the first few months, if I had a sensor reading of 180 mg/dL, I would test my BG, and give myself a correction bolus, even though the pump said “no bolus needed”. Then two hours later, I’d go low, treat, and start an up/down cycle because I hadn’t yet learned to trust the system. Over time, I’ve learned to be comfortable with a glucose level that is not quite ‘perfect’, and trust the system to get me in control. As a result, my glucose is more stable, in my target range more often, and I have a lot less lows and highs.
The Guardian Sensor 3 is accurate and reliable. I’ve gotten to a point that testing my BG is almost exclusively done to calibrate the system and maintain its integrity. The sensor glucose is the number I trust to make decisions. I know that if the system is functioning correctly, I can rely on that.
Important Safety Information
The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products.
Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For complete safety information, please consult the appropriate User Guide.
Tags: clinical trial
, continuous glucose monitor
, diabetes innovation
, Guardian Sensor 3
, hybrid closed loop
, insulin pump
, MiniMed 670G system